Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at HKD 3.79, with a transaction volume of HKD 6.119 million, following the announcement of FDA approval for its eye drop product [1] Group 1: FDA Approval and Product Details - Zhaoke Ophthalmology announced that its partner, Tenpoint Therapeutics, has received FDA approval for the commercialization of Carbachol and Bromonidine Tartrate Eye Drops (2.75%/0.1%) [1] - The eye drop, known as BRIMOCHOL PF during clinical trials, will be marketed in the U.S. under the name YUVEZZI, aimed at treating presbyopia [1] Group 2: Commercial Strategy and Partnerships - The FDA approval is considered a strong catalyst for Zhaoke Ophthalmology as it formulates its commercialization strategy [1] - The company has established a partnership network for BRIMOCHOL PF, which currently includes eight commercial partners across the Asia-Pacific region (including South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan/Hong Kong/Macau, Singapore, and Vietnam) and the Middle East [1] - With FDA recognition, Zhaoke anticipates accelerating the market launch of the drug, marking a significant global milestone [1]

Core Viewpoint - Tenpoint Therapeutics, Ltd. has received FDA approval for the commercialization of BRIMOCHOL PF, an innovative eye drop treatment for presbyopia, which will be marketed as YUVEZZI in the U.S. [1] Group 1 - The approval follows the successful completion of Phase 3 clinical trials, with the first key Phase 3 study (BRIO I) demonstrating the combination therapy's superiority over individual therapies [1] - The second Phase 3 study (BRIO II) achieved all primary endpoints for near vision improvement, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while binocular uncorrected distance visual acuity (BUCDVA) did not decrease by one line or more [1] Group 2 - During the BRIO II study, BRIMOCHOL PF showed good tolerability with no serious treatment-related adverse events reported, and the incidence of eye redness was low [2] - The report rate of eye redness for subjects receiving BRIMOCHOL PF was 2.8%, significantly lower than the 10.7% for those receiving only carbachol [2] Group 3 - This FDA approval serves as a strong catalyst for the company's commercialization strategy, with a partnership network established across the Asia-Pacific region and the Middle East, including eight commercial partners [2] - With FDA recognition, the company anticipates accelerating the market entry of BRIMOCHOL PF, marking an important global milestone [2]

Core Insights - Tenpoint Therapeutics, Ltd. has received FDA approval for the commercialization of BRIMOCHOL PF (2.75%/0.1%), an innovative eye drop for the treatment of presbyopia, which will be marketed as YUVEZZI in the U.S. [1][2] Group 1: Clinical Trial Results - The approval follows the successful completion of Phase 3 clinical trials, with the first key Phase 3 study (BRIO I) demonstrating that the combination therapy is more effective than individual active drug compounds [1] - In the second placebo-controlled Phase 3 study (BRIO II), BRIMOCHOL PF met all primary endpoints for near vision improvement, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while binocular uncorrected distance visual acuity (BUCDVA) did not decrease by one line or more [1] Group 2: Safety and Tolerability - During the monitoring of over 72,000 treatment days in the BRIO II study, BRIMOCHOL PF was well-tolerated, with no treatment-related serious adverse events observed [2] - The incidence of eye redness (conjunctival hyperemia) as a reported adverse event was low, with a rate of 2.8% in BRIMOCHOL PF recipients compared to 10.7% in those receiving only carbachol [2] Group 3: Commercial Strategy - The FDA approval serves as a strong catalyst for the company's commercialization strategy, as it has established a partnership network for BRIMOCHOL PF, including eight commercial partners across the Asia-Pacific region and the Middle East [2] - With FDA recognition, the company anticipates accelerating the market entry of the drug, marking a significant global milestone [2]

Core Viewpoint - Zhaoke Ophthalmology (06622) has expanded its global commercialization footprint by granting exclusive rights for its core presbyopia treatment drug BRIMOCHOL PF to AFT Pharmaceuticals in Singapore and Kenso in Vietnam, enhancing its market presence in eight countries [1] Group 1: Company Developments - Zhaoke Ophthalmology's stock price increased by over 7% during trading, currently up 3.44% at HKD 3.61, with a trading volume of HKD 11.43 million [1] - The company has now extended its global commercialization rights to include markets in South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan, Singapore, and Vietnam [1] Group 2: Partnerships - AFT Pharmaceuticals, based in New Zealand, has been granted exclusive distribution rights in Singapore and operates in over 125 countries [1] - Kenso, a Japanese private pharmaceutical company, has been awarded exclusive distribution rights in Vietnam and focuses on enhancing vision health through original pharmaceuticals [1]

Core Viewpoint - The stock of Zhaoke Ophthalmology-B (06622) has increased by over 5%, reflecting positive market sentiment following the expansion of its partnership agreement with AFT Pharmaceuticals Limited for the commercialization of BRIMOCHOL PF in Singapore [1] Group 1: Partnership Expansion - Zhaoke Ophthalmology-B has expanded its partnership with AFT Pharmaceuticals to commercialize BRIMOCHOL PF in Singapore [1] - The company has also established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen are now the seventh and eighth commercialization partners for BRIMOCHOL PF, indicating the company's commitment to global expansion [1] Group 2: Product Information - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia [1] - The product is a core asset acquired through a licensing agreement with Tenpoint Therapeutics, Ltd. [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at 3.44 HKD with a transaction volume of 1.707 million HKD, following the announcement of expanded partnerships for the commercialization of BRIMOCHOL PF in Singapore and Vietnam [1] Group 1: Partnerships and Agreements - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - Zhaoke has established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, which includes rights for registration, import, promotion, distribution, marketing, and sales [1] Group 2: Product Information - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, representing a core asset acquired through a partnership with Tenpoint Therapeutics, Ltd. [1] - The addition of AFT and Santen as commercialization partners marks the seventh and eighth partners for BRIMOCHOL PF, highlighting the company's commitment to global expansion [1]

Market Overview - The Hong Kong stock index opened slightly higher on January 27, with the Hang Seng Index rising by 0.36% to 26,863.15 points, the Hang Seng Tech Index increasing by 0.16% to 5,734.9 points, and the National Enterprises Index up by 0.28% to 9,173.2 points [1] - Major tech stocks mostly rose, with Alibaba up by 0.97%, Tencent Holdings up by 0.08%, and JD.com down by 0.17% [1] - Automotive stocks were active, with BYD rising by over 1%, while gold stocks saw some increases, with Zijin Mining up by over 4% [1] Company News - China Power (02380.HK) reported a total consolidated electricity sales volume of 10.73105 million MWh for December 2025, a decrease of 2.31% year-on-year, with an annual cumulative total of approximately 126 million MWh, down by 1.27% year-on-year [2] - Harbin Electric (01133.HK) expects a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year [2] - Singularity National Peak (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [3] - East Sunshine Pharmaceutical (06887.HK) has signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for an AI-driven drug research and development platform [4] - Weisheng Pharmaceutical-B (02561.HK) has received approval from the National Medical Products Administration for the marketing authorization application of injectable Long Pei growth hormone [5] - Kexin Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [6] - Zhenghong Pharmaceutical (01276.HK) has received a clinical trial approval notice for SHR-1049 injection [7] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by the relevant bondholders' meeting [8] - Aobo Technology Holdings (08279.HK) has entered into a technical service agreement with Hong Kong Gold Trading Co., Ltd. [9] - Future Data Group (08229.HK) has signed a strategic cooperation framework agreement with Linghe Culture [10] - Haowei Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuan Zhi's initial public offering [11] Institutional Insights - Huatai Securities noted that foreign and southbound capital continues to flow in, with public fund positions in Hong Kong stocks dropping to 23% in Q4, significantly reducing potential selling pressure [12] - Goldman Sachs has raised its year-end gold price forecast from USD 4,900 to USD 5,400 per ounce due to increasing demand from private investors and central banks [12] - CITIC Securities recommends focusing on cloud computing service providers and continuing to recommend AI computing power sectors and AI applications, highlighting the ongoing AI industrial revolution [12]

Group 1 - The company has expanded its partnership with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - A strategic partnership has been established with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, highlighting the company's commitment to global expansion [1] Group 2 - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL PF, with a review deadline set for January 28, 2026 [2]

Group 1 - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - The company has established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize BRIMOCHOL PF in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, marking them as the seventh and eighth commercialization partners for the product [1] Group 2 - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired as a core asset through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL PF, with a review deadline set for January 28, 2026 [2]

Group 1 - The core viewpoint of the article is that Zhaoke Ophthalmology-B (06622) has entered into a strategic partnership with Dongshenghua Pharmaceutical to jointly advance the clinical introduction and future commercialization of BRIMOCHOL PF in Taiwan [1] - Under the agreement, Zhaoke grants Dongshenghua exclusive distributor rights for the registration, importation, promotion, distribution, marketing, and sales of BRIMOCHOL PF in Taiwan [1] - The developer of BRIMOCHOL PF, Tenpoint Therapeutics, Ltd., announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026, under the Prescription Drug User Fee Act (PDUFA) [1]